Evaluation of VEGF-111b Anticancer Peptide Production in Transfected Human Cells Using Real time- PCR Analysis

Background and Endothelial growth factor type b with anti-angiogenic activity and inhibition of tumor growth are considered as new anticancer drugs. The aim of this research was to study the expression of vegf111b in HEK293 human cells.
In this experimental study, HEK293 cells were transfected by pBUD.VEGF111b vector containing the VEGF111B gene through lipofectamine method. The mRNA of transfected cells and control cells were extracted and cDNA was built over it. Then, the expression levels of vegf111b were measured using Real time- PCR.
Transfection of HEK293 cells was successfully done and 48 hours after transfection of HEK293 cells, ct of the vegf111b expression in transfected cells was 23.17 and ct of the GAPDH control gene expression in these cells was 21.11. In the control (untransfected) cells the ct of GAPDH was 21.09 and there was no expression of vegf111b in these cells.
Expression of Vegf111b recombinant protein in HEK293 cells is the first step for further research on this protein. Current study has provided the possibility of using this product for future research on angiogenesis and cancer treatments.